ArticleDiscover oncology2026
Integrated transcriptomics, network pharmacology and clinical expression validation reveal the prognostic significance of PANoptosis-related genes in cordycepin-treated lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have shown that PANoptosis is increasingly involved in cancer and cancer treatment. The Cordycepin has also been found to be involved in the development of various cancers. However, relevant research on both in lung adenocarcinoma (LUAD) remains relatively scarce. The present study aims to identify potential prognostic genes in LUAD and elucidate their impact on the prognosis of LUAD patients, with the goal of providing novel insights into the therapeutic strategies for this disease.
methodsThe target genes for Cordycepin and transcriptomic datasets for LUAD were retrieved from public databases, and PANoptosis-related genes were retrieved from literature. This study employed differential expression analysis, consensus clustering analysis, weighted gene co-expression network analysis (WGCNA), and Cox regression analysis. This study identified potential biomarkers. The backpropagation neural networks (BPNNs) were constructed using these biomarkers. Furthermore, the study delved into underlying biological mechanisms through enrichment analysis. Additional analyses were performed to evaluate functional pathways, immune infiltration, and drug sensitivity in different risk individuals. Finally, clinical samples were collected and biomarker expression was validated using RT-qPCR.
resultsA total of 8 biomarkers including SLC2A1, SMS, CCNA2, CDC25C, RNASE1, NR3C2, CAT, and ADA were identified in this study. Among these, SLC2A1, SMS, CCNA2, CDC25C, and ADA were significantly upregulated in clinical disease samples, while RNASE1, NR3C2, and CAT were significantly downregulated. The GSEA results indicated that the biomarkers were primarily enriched in mismatch repair and proteasome. There were 10 differential immune cells (Macrophages M0, Monocytes, activated dendritic cells, etc.) between two subgroups detected by the CIBERSORT algorithm. Meanwhile, 18 differential immune cells including Activated CD4+ T cells, Memory B cells, Natural killer T cells, etc. were identified using the ssGSEA algorithm. The analysis of drug sensitivity showed significant differences in 22 drugs between the two risk groups.
conclusionOur results suggested that 8 biomarkers including SLC2A1, SMS, CCNA2, CDC25C, RNASE1, NR3C2, CAT, and ADA were associated with PANoptosis in LUAD. These findings may provide supportive evidence for the prognosis prediction and treatment of LUAD. However, the involvement of these genes in PANoptosis is currently only a hypothesis based on bioinformatics analysis and requires further experimental validation in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.